My colleagues at FTI have a new white paper out surveying health care leaders on trends to expect in 2022. The data come from a survey of 251 senior decision makers working in corporate
communications, investor relations, public affairs, business development, R&D and marketing for healthcare and life sciences companies in the U.S. Some key findings:
More than two-thirds (69%) expect significant policy changes will be made on drug pricing under the Biden Administration over the next 12 months.
Deal-making is anticipated to rise in 2022. The most significant increase is expected in healthcare IPO activity, with 65% (+12% since 2020) expecting it to be higher in 2022,
and 1 in 4 (24%) expecting it to be “far higher.” Nearly 7 in 10 (65%) expect M&A activity to be higher in 2022, rising +5% from last year, and majority (57%) also foresee higher SPAC
activity in 2022 than in the previous 12 months.
Hybrid vs. in-person workplace
When it comes to planning a return to the workplace, 78% are optimistic that a
workable balance can be found. Companies are, however, split in their approach, with
49% planning to offer a hybrid working approach, while 43% are considering returning to pre-pandemic working.